All Stories

  1. Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators’ viewpoint

    Article • Cardiology Journal, February 2025, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  2. Prolonged antithrombotic treatment after de-escalation of dual antiplatelet therapy in patients after acute coronary syndrome - which strategy should be applied? The ELECTRA-SIRIO 2 investigators standpoint

    Article • International Journal of Cardiology, February 2025, Elsevier

    Professor Jolanta M Siller-Matula

  3. International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention

    Article • JACC Cardiovascular Interventions, November 2024, Elsevier

    Professor Jolanta M Siller-Matula

  4. Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial

    Article • Clinical Research in Cardiology, September 2024, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  5. Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial

    Article • Resuscitation, August 2024, Elsevier

    Professor Jolanta M Siller-Matula

  6. Ticagrelor downregulates the expression of proatherogenic and proinflammatory miR125-b compared to clopidogrel: A randomized, controlled trial

    Article • International Journal of Cardiology, July 2024, Elsevier

    Professor Jolanta M Siller-Matula

  7. Alteration of circulating ACE2-network related microRNAs in patients with COVID-19

    Article • Scientific Reports, June 2024, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  8. Abbreviated dual antiplatelet therapy after acute coronary syndrome

    Article • The Lancet, May 2024, Elsevier

    Professor Jolanta M Siller-Matula

  9. Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry

    Article • JACC Advances, April 2024, Elsevier

    Professor Jolanta M Siller-Matula

  10. The interaction between non-coding RNAs and SGLT2: A review

    Article • International Journal of Cardiology, March 2024, Elsevier

    Professor Jolanta M Siller-Matula

  11. The quality of care and long-term mortality of out of hospital cardiac arrest survivors after acute myocardial infarction: a nationwide cohort study

    Article • European Heart Journal - Quality of Care and Clinical Outcomes, February 2024, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  12. Commissural alignment during TAVR reduces the risk of overlap to coronary ostia

    Article • International Journal of Cardiology, January 2024, Elsevier

    Professor Jolanta M Siller-Matula

  13. Timing of SGLT2i initiation after acute myocardial infarction

    Article • Cardiovascular Diabetology, September 2023, Springer Science + Business Media

    Dr. Faisal Aziz, Professor Jolanta M Siller-Matula

  14. Clinical outcomes associated with type II myocardial infarction caused by bleeding

    Article • American Heart Journal, September 2023, Elsevier

    Professor Jolanta M Siller-Matula

  15. 2023 ESC Guidelines for the management of acute coronary syndromes

    Article • European Heart Journal, August 2023, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  16. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry

    Article • EP Europace, August 2023, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  17. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis

    Article • Nature Reviews Cardiology, July 2023, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  18. Endovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: A non-inferiority meta-analysis of 6 randomised controlled trials

    Article • Vascular Pharmacology, June 2023, Elsevier

    Professor Jolanta M Siller-Matula

  19. Effects of empagliflozin in women and men with acute myocardial infarction – an analysis from the EMMY trial

    Article • Hellenic Journal of Cardiology, May 2023, Elsevier

    Professor Jolanta M Siller-Matula, Dr. Faisal Aziz

  20. Expression Patterns of MiR-125a and MiR-223 and Their Association with Diabetes Mellitus and Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome

    Article • Biomedicines, April 2023, MDPI AG

    Professor Jolanta M Siller-Matula

  21. Sex Differences in Clinical Profile and Outcome After Percutaneous Coronary Intervention for Chronic Total Occlusion

    Article • Cardiovascular Revascularization Medicine, April 2023, Elsevier

    Professor Jolanta M Siller-Matula

  22. Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

    Article • Heart International, January 2023, Touch Digital Media, Ltd.

    Professor Jolanta M Siller-Matula

  23. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study

    Article • EuroIntervention, December 2022, Europa Digital & Publishing

    Professor Jolanta M Siller-Matula

  24. Expression of miR-223 to predict outcomes after transcatheter aortic valve implantation

    Article • Cardiology Journal, October 2022, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  25. Corrigendum to ‘Outcomes of Percutaneous Coronary Intervention in Patients With Acquired Immunosuppression‘ The American Journal of Cardiology Volume 171, 15 May 2022, Pages 40-48

    Article • The American Journal of Cardiology, September 2022, Elsevier

    Professor Jolanta M Siller-Matula

  26. Empagliflozin in acute Myocardial Infarction: the EMMY trial

    Article • European Heart Journal, August 2022, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  27. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

    Article • European Heart Journal, August 2022, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula, Prof HECTOR BUENO

  28. Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis

    Article • Frontiers in Pharmacology, August 2022, Frontiers

    Professor Jolanta M Siller-Matula

  29. Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19

    Article • RNA Biology, August 2022, Taylor & Francis

    Professor Jolanta M Siller-Matula

  30. Echocardiographic predictors of presence of cardiac amyloidosis in aortic stenosis

    Article • European Heart Journal - Cardiovascular Imaging, August 2022, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  31. Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease

    Article • Frontiers in Cardiovascular Medicine, July 2022, Frontiers

    Professor Jolanta M Siller-Matula

  32. Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022

    Article • Cardiology Journal, July 2022, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  33. Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study

    Article • Cardiovascular Diabetology, May 2022, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  34. Impact of pre-existing vascular disease on clinical outcomes

    Article • European Heart Journal - Quality of Care and Clinical Outcomes, May 2022, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  35. High concentration of symmetric dimethylarginine is associated with low platelet reactivity and increased bleeding risk in patients with acute coronary syndrome

    Article • Thrombosis Research, May 2022, Elsevier

    Professor Jolanta M Siller-Matula

  36. Outcomes of Percutaneous Coronary Intervention in Patients With Acquired Immunosuppression

    Article • The American Journal of Cardiology, May 2022, Elsevier

    Professor Jolanta M Siller-Matula

  37. Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial

    Article • Thrombosis Journal, April 2022, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  38. Simplified Acute Physiology Score 3 Performance in Austrian COVID-19 Patients Admitted to Intensive Care Units with and without Diabetes

    Article • Viruses, April 2022, MDPI AG

    Professor Jolanta M Siller-Matula

  39. The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis

    Article • Platelets, March 2022, Taylor & Francis

    Professor Jolanta M Siller-Matula

  40. Reply

    Article • JACC Cardiovascular Interventions, March 2022, Elsevier

    Professor Jolanta M Siller-Matula

  41. Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality

    Article • Journal of Personalized Medicine, February 2022, MDPI AG

    Professor Jolanta M Siller-Matula

  42. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis

    Article • Frontiers in Immunology, February 2022, Frontiers

    Professor Jolanta M Siller-Matula

  43. External stenting of saphenous vein grafts for coronary artery bypass: a single-center analysis of clinical outcomes

    Article • The Journal of Cardiovascular Surgery, January 2022, Edizioni Minerva Medica

    Professor Jolanta M Siller-Matula

  44. Simplified Acute Physiology Score 3 Performance in Austrian COVID-19 Patients with and Without Diabetes

    Article • December 2021, Research Square

    Professor Jolanta M Siller-Matula

  45. Anticoagulant Treatment Regimens in Patients with Covid‐19: A Meta‐Analysis

    Article • Clinical Pharmacology & Therapeutics, December 2021, Wiley

    Professor Jolanta M Siller-Matula

  46. Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement

    Article • JACC Cardiovascular Interventions, December 2021, Elsevier

    Professor Jolanta M Siller-Matula

  47. COVID-19 In-Hospital Mortality in People with Diabetes Is Driven by Comorbidities and Age—Propensity Score-Matched Analysis of Austrian National Public Health Institute Data

    Article • Viruses, November 2021, MDPI AG

    Professor Jolanta M Siller-Matula

  48. Mean platelet volume-to-platelet count ratio after elective cardiac surgical procedures is superior in reflecting platelets metabolic hyperactivity compared to other routine morphological platelet indices: A preliminary report

    Article • Cardiology Journal, November 2021, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  49. Impact of sex on outcomes of percutaneous coronary intervention for chronic total occlusion: A meta‐analysis

    Article • Catheterization and Cardiovascular Interventions, November 2021, Wiley

    Professor Jolanta M Siller-Matula

  50. Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure

    Article • Biomedicine & Pharmacotherapy, November 2021, Elsevier

    Professor Jolanta M Siller-Matula

  51. Plasma Trimethylamine-N-Oxide Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome

    Article • Frontiers in Cardiovascular Medicine, October 2021, Frontiers

    Professor Jolanta M Siller-Matula

  52. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients

    Article • Cardiology Journal, October 2021, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  53. Thrombosis and fibrinolysis in atherosclerotic cardiovascular disease: it takes two to tango

    Article • European Heart Journal, October 2021, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  54. Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis

    Article • Journal of Personalized Medicine, October 2021, MDPI AG

    Professor Jolanta M Siller-Matula

  55. Meta-Analysis of Transradial Versus Transfemoral Access for Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease

    Article • The American Journal of Cardiology, October 2021, Elsevier

    Professor Jolanta M Siller-Matula

  56. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial

    Article • Cardiology Journal, September 2021, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  57. Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?

    Article • Cardiology Journal, August 2021, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  58. Women leaders in Cardiology. Contemporary profile of the WHO European region

    Article • European Heart Journal Open, July 2021, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  59. Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis

    Article • Frontiers in Cardiovascular Medicine, July 2021, Frontiers

    Professor Jolanta M Siller-Matula

  60. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study

    Article • Cardiology Journal, July 2021, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  61. Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different mates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries

    Article • Circulation Cardiovascular Quality and Outcomes, June 2021, Wolters Kluwer Health

    Professor Jolanta M Siller-Matula

  62. Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis

    Article • Vascular Pharmacology, June 2021, Elsevier

    Professor Jolanta M Siller-Matula

  63. MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus

    Article • Journal of Clinical Medicine, May 2021, MDPI AG

    Professor Jolanta M Siller-Matula

  64. Platelet function in patients undergoing surgical and transcatheter aortic valve replacement: a comparative study

    Article • Kardiologia Polska, April 2021, Polskie Towarzystwo Kardiologiczne

    Professor Jolanta M Siller-Matula

  65. MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review

    Article • Frontiers in Physiology, April 2021, Frontiers

    Professor Jolanta M Siller-Matula

  66. Comparison of high-sensitivity C-reactive protein vs. C-reactive protein for diagnostic accuracy and prediction of mortality in patients with acute myocardial infarction

    Article • Annals of Clinical Biochemistry International Journal of Laboratory Medicine, March 2021, SAGE Publications

    Professor Jolanta M Siller-Matula

  67. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis

    Article • Clinical Pharmacology & Therapeutics, March 2021, Wiley

    Professor Jolanta M Siller-Matula

  68. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics

    Article • Cardiovascular Diabetology, February 2021, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  69. Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists

    Article • ESC Heart Failure, February 2021, Wiley

    Professor Jolanta M Siller-Matula

  70. The Intra-Aortic Balloon Pump

    Article • Journal of Visualized Experiments, February 2021, MyJove Corporation

    Professor Jolanta M Siller-Matula

  71. Sex Differences in Treatment and Outcomes in Non-ST-Elevation Acute Coronary Syndrome

    Article • Circulation Cardiovascular Interventions, January 2021, Wolters Kluwer Health

    Professor Jolanta M Siller-Matula

  72. Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement

    Article • European Heart Journal - Cardiovascular Imaging, December 2020, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  73. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease

    Article • American Journal of Therapeutics, December 2020, Wolters Kluwer Health

    Professor Jolanta M Siller-Matula

  74. ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors

    Article • Journal of Clinical Medicine, November 2020, MDPI AG

    Professor Jolanta M Siller-Matula

  75. Editorial: Antithrombotic Treatment in Transcatheter Structural Cardiac Interventions and After Cardiac Device Implantation

    Article • Frontiers in Cardiovascular Medicine, November 2020, Frontiers

    Professor Jolanta M Siller-Matula

  76. Differential Effects of Clopidogrel with or without Aspirin on Platelet Reactivity and Coagulation Activation: a randomized trial in healthy volunteers

    Article • Clinical Pharmacology & Therapeutics, November 2020, Wiley

    Professor Jolanta M Siller-Matula

  77. MicroRNAs and Long Noncoding RNAs in Coronary Artery Disease

    Article • Cardiology Clinics, November 2020, Elsevier

    Professor Jolanta M Siller-Matula

  78. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines

    Article • Cardiology Journal, October 2020, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  79. MicroRNAs as Biomarkers of Systemic Changes in Response to Endurance Exercise—A Comprehensive Review

    Article • Diagnostics, October 2020, MDPI AG

    Professor Jolanta M Siller-Matula

  80. Cardiac Arrest and Related Mortality in Emergency Departments in the United States: Analysis of the Nationwide Emergency Department Sample

    Article • Resuscitation, October 2020, Elsevier

    Professor Jolanta M Siller-Matula

  81. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome

    Article • Vascular Pharmacology, October 2020, Elsevier

    Professor Jolanta M Siller-Matula

  82. Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry

    Article • Internal and Emergency Medicine, September 2020, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  83. Volume Status Impacts CMR–Extracellular Volume Measurements and Outcome in AS Undergoing TAVR

    Article • JACC Cardiovascular Imaging, September 2020, Elsevier

    Professor Jolanta M Siller-Matula

  84. Medication adherence and its determinants in patients after myocardial infarction

    Article • Scientific Reports, July 2020, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  85. von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo

    Article • Thrombosis and Haemostasis, July 2020, Thieme Publishing Group

    Professor Jolanta M Siller-Matula

  86. Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report

    Article • European Heart Journal - Case Reports, June 2020, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  87. Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement

    Article • European Heart Journal - Cardiovascular Imaging, June 2020, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  88. Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients

    Article • European Journal of Clinical Investigation, June 2020, Wiley

    Professor Jolanta M Siller-Matula

  89. Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS

    Article • Platelets, June 2020, Taylor & Francis

    Professor Jolanta M Siller-Matula

  90. Prediction for Contrast Volume in Transcatheter Aortic Valve Replacement – Important but Modifiable?

    Article • Cardiology, June 2020, Karger Publishers

    Professor Jolanta M Siller-Matula

  91. Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies

    Article • International Journal of Cardiology, June 2020, Elsevier

    Professor Jolanta M Siller-Matula

  92. Genome‐wide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the International Clopidogrel Pharmacogenomics Consortium (ICPC)

    Article • Clinical Pharmacology & Therapeutics, May 2020, Wiley

    Professor Jolanta M Siller-Matula

  93. ACE2 interaction networks in COVID-19: a physiological framework for prediction of outcome in patients with cardiovascular risk factors

    Article • May 2020, Cold Spring Harbor Laboratory Press

    Professor Jolanta M Siller-Matula

  94. Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type

    Article • Journal of Clinical Medicine, April 2020, MDPI AG

    Professor Jolanta M Siller-Matula

  95. Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis

    Article • Atherosclerosis, April 2020, Elsevier

    Professor Jolanta M Siller-Matula

  96. Left Main Coronary Artery Disease and Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions

    Article • Journal of Clinical Medicine, March 2020, MDPI AG

    Professor Jolanta M Siller-Matula

  97. Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with th...

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, March 2020, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  98. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—The EMMY trial

    Article • American Heart Journal, March 2020, Elsevier

    Professor Jolanta M Siller-Matula

  99. Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome

    Article • European Journal of Heart Failure, February 2020, Wiley

    Professor Jolanta M Siller-Matula

  100. Impact of pre‐admission morphine on re‐infarction in patients with STEMI treated with PPCI: a meta‐analysis

    Article • Clinical Pharmacology & Therapeutics, January 2020, Wiley

    Professor Jolanta M Siller-Matula

  101. Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention

    Article • Advances in Interventional Cardiology, January 2020, Termedia Sp. z.o.o.

    Professor Jolanta M Siller-Matula

  102. Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome

    Article • European Heart Journal, December 2019, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  103. Transcatheter versus surgical aortic valve replacement in low-risk patients: a meta-analysis of randomized trials

    Article • Clinical Research in Cardiology, December 2019, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  104. Ticagrelor attenuates the increase of extracellular vesicles concentrations in plasma after acute myocardial infarction compared to clopidogrel

    Article • Journal of Thrombosis and Haemostasis, December 2019, Wiley

    Professor Jolanta M Siller-Matula

  105. Impact of Antiplatelet Therapies on Patients Outcome in Osteosynthetic Surgery of Proximal Femoral Fractures

    Article • Journal of Clinical Medicine, December 2019, MDPI AG

    Professor Jolanta M Siller-Matula

  106. Bioresorbable Vascular Scaffolds—Dead End or Still a Rough Diamond?

    Article • Journal of Clinical Medicine, December 2019, MDPI AG

    Professor Jolanta M Siller-Matula

  107. Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing

    Article • Frontiers in Cardiovascular Medicine, December 2019, Frontiers

    Professor Jolanta M Siller-Matula

  108. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups

    Article • BMC Medicine, November 2019, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  109. Aortic valve stenosis awareness in Austria—results of a nationwide survey in 1001 subjects

    Article • Wiener Medizinische Wochenschrift, September 2019, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  110. Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, September 2019, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  111. Transcatheter Aortic Valve Replacement Is Associated with Less Oxidative Stress and Faster Recovery of Antioxidant Capacity than Surgical Aortic Valve Replacement

    Article • Journal of Clinical Medicine, September 2019, MDPI AG

    Professor Jolanta M Siller-Matula, Professor Przemyslaw Niedzielski

  112. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review

    Article • Cardiovascular Diabetology, August 2019, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  113. Differential Effects of Ticagrelor with or without Aspirin on Platelet Reactivity and Coagulation Activation: a randomized trial in healthy volunteers

    Article • Clinical Pharmacology & Therapeutics, August 2019, Wiley

    Professor Jolanta M Siller-Matula

  114. Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies

    Article • International Journal of Cardiology, July 2019, Elsevier

    Professor Jolanta M Siller-Matula

  115. Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study

    Article • Scientific Reports, June 2019, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  116. Shedding Light on Long-Term Effects of Early Antiplatelet Strategies After Fibrinolytic Treatment in STEMI

    Article • Journal of the American College of Cardiology, June 2019, Elsevier

    Professor Jolanta M Siller-Matula

  117. Effectiveness of antiplatelet drugs under therapeutic hypothermia a comprehensive review

    Article • Clinical Pharmacology & Therapeutics, May 2019, Wiley

    Professor Jolanta M Siller-Matula

  118. Aortenklappenerkrankungen: Wann und wie sanieren?

    Article • MMW - Fortschritte der Medizin, April 2019, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  119. Switching between P2Y12 antagonists – From bench to bedside

    Article • Vascular Pharmacology, April 2019, Elsevier

    Professor Jolanta M Siller-Matula

  120. Platelet reactivity patterns in patients treated with dual antiplatelet therapy

    Article • European Journal of Clinical Investigation, March 2019, Wiley

    Professor Jolanta M Siller-Matula

  121. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis

    Article • Thrombosis and Haemostasis, March 2019, Thieme Publishing Group

    Professor Jolanta M Siller-Matula

  122. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)

    Article • BMJ Open, March 2019, BMJ

    Professor Jolanta M Siller-Matula

  123. Net Clinical Benefit of Non-Vitamin K Antagonist Versus Vitamin K Antagonist Anticoagulants in Elderly Patients With Atrial Fibrillation

    Article • The American Journal of Medicine, January 2019, Elsevier

    Professor Jolanta M Siller-Matula

  124. METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS—The METAMORPHOSIS Trial

    Article • Thrombosis and Haemostasis, November 2018, Thieme Publishing Group

    Professor Jolanta M Siller-Matula

  125. Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients

    Article • Journal of Clinical Medicine, November 2018, MDPI AG

    Professor Jolanta M Siller-Matula

  126. Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires?

    Article • Current Medical Research and Opinion, September 2018, Taylor & Francis

    Aldona Kubica, Professor Jolanta M Siller-Matula

  127. Coming Closer to Personalized Medicine in Transcatheter Aortic Valve Replacement

    Article • JACC Cardiovascular Interventions, September 2018, Elsevier

    Professor Jolanta M Siller-Matula

  128. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy

    Article • International Journal of Cardiology, August 2018, Elsevier

    Professor Jolanta M Siller-Matula

  129. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries

    Article • International Journal of Cardiology, June 2018, Elsevier

    Professor Jolanta M Siller-Matula

  130. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

    Article • American Heart Journal, April 2018, Elsevier

    Professor Jolanta M Siller-Matula

  131. Impaired aspirin-mediated platelet function inhibition in resuscitated patients with acute myocardial infarction treated with therapeutic hypothermia: a prospective, observational, non-randomized single-centre study

    Article • Annals of Intensive Care, February 2018, Springer Science + Business Media

    Peter P Rainer, Professor Jolanta M Siller-Matula

  132. Ticagrelor – toward more efficient platelet inhibition and beyond

    Article • Therapeutics and Clinical Risk Management, January 2018, Dove Medical Press

    Professor Jolanta M Siller-Matula

  133. Genetic variability of SRC family kinases and its association with platelet hyperreactivity and clinical outcomes: a systematic review

    Article • Current Pharmaceutical Design, December 2017, Bentham Science Publishers

    Professor Jolanta M Siller-Matula

  134. Clopidogrel in Critically Ill Patients

    Article • Clinical Pharmacology & Therapeutics, November 2017, Wiley

    Professor Jolanta M Siller-Matula

  135. Platelets redox balance assessment: Current evidence and methodological considerations

    Article • Vascular Pharmacology, August 2017, Elsevier

    Professor Jolanta M Siller-Matula

  136. Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention

    Article • Thrombosis and Haemostasis, July 2017, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  137. Prasugrel in critically ill patients

    Article • Thrombosis and Haemostasis, July 2017, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  138. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF ( PRE vention o F ...

    Article • Journal of the American Heart Association, July 2017, Wolters Kluwer Health

    Professor Jolanta M Siller-Matula

  139. Leczenie antyagregacyjne u pacjentów z ostrym zespołem wieńcowym — zalecenia dla zespołów ratownictwa medycznego. Stanowisko ekspertów

    Article • Kardiologia Polska, April 2017, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  140. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina

    Article • Thrombosis and Haemostasis, February 2017, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  141. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, February 2017, Oxford University Press (OUP)

    Professor Jolanta M Siller-Matula

  142. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study

    Article • International Journal of Cardiology, January 2017, Elsevier

    Professor Jolanta M Siller-Matula

  143. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients

    Article • British Journal of Clinical Pharmacology, July 2016, Wiley

    Professor Jolanta M Siller-Matula

  144. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors

    Article • International Journal of Cardiology, July 2016, Elsevier

    Professor Jolanta M Siller-Matula

  145. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor

    Article • Vascular Pharmacology, April 2016, Elsevier

    Professor Jolanta M Siller-Matula

  146. Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention

    Article • Thrombosis Research, February 2016, Elsevier

    Professor Jolanta M Siller-Matula

  147. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor

    Article • Platelets, November 2015, Taylor & Francis

    Professor Jolanta M Siller-Matula

  148. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial

    Article • European Heart Journal, October 2015, European Society of Cardiology

    Professor Jolanta M Siller-Matula

  149. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis

    Article • European Heart Journal Acute Cardiovascular Care, May 2015, SAGE Publications

    Professor Jolanta M Siller-Matula, Dr Marie Lordkipanidzé

  150. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention

    Article • European Heart Journal, April 2015, European Society of Cardiology

    Dr Dániel Aradi, Professor Jolanta M Siller-Matula

  151. Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREDICT-STABLE)

    Article • PLOS One, March 2015, PLOS

    Professor Jolanta M Siller-Matula

  152. Intraoperative imprint cytology for real-time assessment of surgical margins during partial nephrectomy: A comparison with frozen section

    Article • Urologic Oncology Seminars and Original Investigations, February 2015, Elsevier

    Professor Jolanta M Siller-Matula

  153. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention

    Article • Clinical Science, January 2015, Portland Press Ltd.

    Professor Jolanta M Siller-Matula

  154. Personalized antiplatelet therapy with P2Y 12 receptor inhibitors: benefits and pitfalls

    Article • Advances in Interventional Cardiology, January 2015, Termedia Sp. z.o.o.

    Professor Jolanta M Siller-Matula

  155. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction

    Article • European Journal of Pharmacology, November 2014, Elsevier

    Professor Jolanta M Siller-Matula

  156. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up

    Article • Cardiology Journal, October 2014, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  157. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry

    Article • BMJ Open, October 2014, BMJ

    Professor Jolanta M Siller-Matula

  158. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?

    Article • Thrombosis and Haemostasis, September 2014, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  159. Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention

    Article • PLOS One, July 2014, PLOS

    Professor Jolanta M Siller-Matula

  160. Duale Plättchenhemmung in der Intensivmedizin

    Article • Medizinische Klinik - Intensivmedizin und Notfallmedizin, July 2014, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  161. Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention

    Article • Thrombosis and Haemostasis, March 2014, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  162. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb

    Article • Platelets, February 2014, Taylor & Francis

    Professor Jolanta M Siller-Matula

  163. Mutations and polymorphisms of the alpha-galactosidase A gene in patients with hypertrophic cardiomyopathy

    Article • Molecular Genetics and Metabolism, February 2014, Elsevier

    Professor Jolanta M Siller-Matula

  164. Cangrelor: an emerging therapeutic option for patients with coronary artery disease

    Article • Current Medical Research and Opinion, January 2014, Informa Healthcare

    Professor Jolanta M Siller-Matula

  165. Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors

    Article • Journal of Thrombosis and Haemostasis, January 2014, Elsevier

    Professor Jolanta M Siller-Matula

  166. Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases: A Systematic Review and Meta-Analysis

    Article • Stroke, December 2013, Wolters Kluwer Health

    Professor Jolanta M Siller-Matula

  167. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding

    Article • Journal of the American College of Cardiology, December 2013, Elsevier

    Dr laurent bonello, Professor Jolanta M Siller-Matula

  168. Association of endostatin with mortality in patients with chronic heart failure

    Article • European Journal of Clinical Investigation, November 2013, Wiley

    Professor Jolanta M Siller-Matula

  169. Response Variability to P2Y12 Receptor Inhibitors

    Article • JACC Cardiovascular Interventions, November 2013, Elsevier

    Professor Jolanta M Siller-Matula

  170. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

    Article • International Journal of Cardiology, September 2013, Elsevier

    Professor Jolanta M Siller-Matula

  171. Why have studies of tailored anti-platelet therapy failed so far?

    Article • Thrombosis and Haemostasis, July 2013, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  172. Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy

    Article • Thrombosis Research, July 2013, Elsevier

    Professor Jolanta M Siller-Matula

  173. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin

    Article • International Journal of Cardiology, July 2013, Elsevier

    Professor Jolanta M Siller-Matula

  174. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts’ standpoint

    Article • Cardiology Journal, January 2013, VM Media SP. zo.o VM Group SK

    Professor Jolanta M Siller-Matula

  175. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial

    Article • Clinical Science, November 2012, Portland Press Ltd.

    Professor Jolanta M Siller-Matula

  176. Peer review versus editorial review and their role in innovative science

    Article • Theoretical Medicine and Bioethics, October 2012, Springer Science + Business Media

    Ass.-Prof. Peter Weinberger, Professor Jolanta M Siller-Matula, Dr Jafar +989131081322 Kolahi

  177. Continuous thrombin infusion leads to a bleeding phenotype in sheep

    Article • Thrombosis Research, August 2012, Elsevier

    Professor Jolanta M Siller-Matula

  178. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats

    Article • Thrombosis Research, July 2012, Elsevier

    Professor Jolanta M Siller-Matula

  179. Hemorrhagic Complications Associated With Aspirin

    Article • JAMA, June 2012, American Medical Association (AMA)

    Professor Jolanta M Siller-Matula

  180. ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion

    Article • Arteriosclerosis Thrombosis and Vascular Biology, April 2012, Wolters Kluwer Health

    Professor Jolanta M Siller-Matula

  181. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study

    Article • Journal of Thrombosis and Haemostasis, March 2012, Wiley

    Professor Jolanta M Siller-Matula

  182. The effect of erythropoietin on platelet and endothelial activation markers: A prospective trial in healthy volunteers

    Article • Platelets, November 2011, Taylor & Francis

    Professor Jolanta M Siller-Matula

  183. Thrombin as a multi-functional enzyme

    Article • Thrombosis and Haemostasis, October 2011, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  184. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis

    Article • Journal of Thrombosis and Haemostasis, September 2011, Wiley

    Professor Jolanta M Siller-Matula

  185. Pharmacokinetic basis of the antiplatelet action of prasugrel

    Article • Fundamental and Clinical Pharmacology, September 2011, Wiley

    Professor Jolanta M Siller-Matula

  186. The Authors' reply

    Article • Heart, June 2011, BMJ

    Professor Jolanta M Siller-Matula

  187. Diurnal variation in platelet inhibition by clopidogrel

    Article • Platelets, May 2011, Taylor & Francis

    Professor Jolanta M Siller-Matula

  188. Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding

    Article • Evidence-Based Medicine, May 2011, BMJ

    Professor Jolanta M Siller-Matula

  189. Platelet function variability and non-genetic causes

    Article • Thrombosis and Haemostasis, April 2011, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  190. Genetic variability in response to clopidogrel therapy and its clinical implications

    Article • Thrombosis and Haemostasis, April 2011, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  191. Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration

    Article • Thrombosis and Haemostasis, February 2011, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  192. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura

    Article • Thrombosis and Haemostasis, December 2010, Schattauer GmbH

    Professor Paul Knoebl, Professor Jolanta M Siller-Matula

  193. Adenosine diphosphate induced platelet aggregation is markedly increased in patients with ischemia-triggered cardiac arrest achieving ROSC

    Article • Resuscitation, December 2010, Elsevier

    Professor Jolanta M Siller-Matula

  194. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis

    Article • Journal of Thrombosis and Haemostasis, December 2010, Wiley

    Professor Jolanta M Siller-Matula

  195. Targeting von Willebrand factor and platelet glycoprotein Ib receptor

    Article • Expert Review of Cardiovascular Therapy, December 2010, Taylor & Francis

    Professor Jolanta M Siller-Matula

  196. An experimental model to study isolated effects of thrombin in vivo

    Article • Thrombosis Research, November 2010, Elsevier

    Professor Jolanta M Siller-Matula

  197. Ticagrelor: from discovery to Phase III clinical trial

    Article • Future Cardiology, November 2010, Future Medicine

    Professor Jolanta M Siller-Matula

  198. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation

    Article • Thrombosis and Haemostasis, October 2010, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  199. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

    Article • Heart, August 2010, BMJ

    Professor Jolanta M Siller-Matula

  200. Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans

    Article • Platelets, June 2010, Taylor & Francis

    Professor Jolanta M Siller-Matula

  201. Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points

    Article • Clinical Research in Cardiology, April 2010, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  202. EFFECT OF PROTON PUMP INHIBITORS ON OUTCOME OF PATIENTS DISCHARGED ON DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION AND STENT IMPLANTATION

    Article • Journal of the American College of Cardiology, March 2010, Elsevier

    Professor Jolanta M Siller-Matula

  203. EFFECT OF PROTON PUMP INHIBITORS ON CLINICAL OUTCOME IN PATIENTS TREATED WITH CLOPIDOGREL: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Article • Journal of the American College of Cardiology, March 2010, Elsevier

    Professor Jolanta M Siller-Matula

  204. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay

    Article • Journal of Thrombosis and Haemostasis, February 2010, Wiley

    Professor Jolanta M Siller-Matula

  205. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo

    Article • Transfusion, January 2010, Wiley

    Professor Paul Knoebl, Professor Jolanta M Siller-Matula

  206. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases

    Article • British Journal of Pharmacology, December 2009, Wiley

    Professor Jolanta M Siller-Matula

  207. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers

    Article • Thrombosis and Haemostasis, July 2009, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  208. Response to Letter by Tho

    Article • American Heart Journal, July 2009, Elsevier

    Professor Jolanta M Siller-Matula

  209. Response to Letter by van Werkum: Proton pump inhibitors and clopidogrel: a difficult dilemma

    Article • American Heart Journal, June 2009, Elsevier

    Professor Jolanta M Siller-Matula

  210. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation

    Article • Thrombosis Research, April 2009, Elsevier

    Professor Jolanta M Siller-Matula

  211. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

    Article • American Heart Journal, January 2009, Elsevier

    Professor Jolanta M Siller-Matula

  212. Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel

    Article • Journal of the American College of Cardiology, November 2008, Elsevier

    Professor Jolanta M Siller-Matula

  213. Strain differences in toxic effects of long-lasting isoflurane anaesthesia between Wistar rats and Sprague Dawley rats

    Article • Food and Chemical Toxicology, November 2008, Elsevier

    Professor Jolanta M Siller-Matula

  214. Interspecies differences in coagulation profile

    Article • Thrombosis and Haemostasis, August 2008, Schattauer GmbH

    Professor Jolanta M Siller-Matula

  215. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay

    Article • Platelets, January 2008, Taylor & Francis

    Professor Jolanta M Siller-Matula

  216. Calcium channel blockers reduce the antiplatelet effect of clopidogrel

    Article • BMC Pharmacology, January 2008, Springer Science + Business Media

    Professor Jolanta M Siller-Matula

  217. Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance

    Article • Thrombosis and Haemostasis, February 2007, Schattauer GmbH

    Professor Jolanta M Siller-Matula